United Airlines CEO confirms he approached American Airlines about merger
United CEO Scott Kirby said American rejected the idea, “and without a willing partner, something this big simply can’t get done.”
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
UK royals head to the U.S. in the wake of war, shooting and rocky relations
The trip comes at a tricky time for the U.S. and one of its closest allies, the U.K.
Europe’s rearmament push drives global military spending to record $2.9 trillion despite U.S. pullback
Global military spending rose for an 11th straight year to a record $2.89 trillion in 2025, driven by Europe’s rearmament push, even as U.S. outlays declined.
We spoke to over 30 CEOs and business leaders. Here’s what worries them most
Business leaders across the world are confronting a new operating reality: one where war, inflation and artificial intelligence are part of the baseline.
Japan to tighten rules for shareholder proposals amid pushback against activism
Japan is moving to tighten the criteria for submitting shareholder proposals amid growing backlash from firms pressured by activist investors.
Iran reportedly proposes Hormuz Strait deal to U.S. Here’s where things stand — and what’s next for markets
U.S.-Iran peace talks stall. Here’s where things stand — and what’s next for markets
European markets close lower as Iran reportedly makes peace proposal
European stocks closed lower at the start of the new trading week as investors keep a close eye on stalled Iran-U.S. peace talks.
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
Sun Pharma shares jump 7% as India’s largest drugmaker to buy U.S. firm Organon in $11.75 billion deal
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
